X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1338) 1338
index medicus (855) 855
oncology (788) 788
male (785) 785
female (769) 769
middle aged (698) 698
adult (641) 641
hematology (604) 604
aged (568) 568
aggressive lymphoma (476) 476
non-hodgkins-lymphoma (465) 465
chemotherapy (421) 421
prognosis (409) 409
antineoplastic combined chemotherapy protocols - therapeutic use (404) 404
cancer (354) 354
treatment outcome (346) 346
lymphomas (285) 285
rituximab (273) 273
adolescent (271) 271
elderly-patients (265) 265
aged, 80 and over (233) 233
cyclophosphamide - administration & dosage (218) 218
lymphoma (218) 218
retrospective studies (209) 209
aggressive lymphomas (208) 208
lymphoma, large b-cell, diffuse - drug therapy (200) 200
disease-free survival (194) 194
doxorubicin - administration & dosage (190) 190
vincristine - administration & dosage (190) 190
lymphoma, non-hodgkin - drug therapy (189) 189
antineoplastic combined chemotherapy protocols - administration & dosage (188) 188
care and treatment (184) 184
pathology (177) 177
survival analysis (173) 173
transplantation (172) 172
prednisone - administration & dosage (170) 170
young adult (169) 169
tumors (165) 165
survival (158) 158
survival rate (156) 156
b-cell lymphoma (148) 148
medicine & public health (146) 146
analysis (142) 142
therapy (142) 142
combined modality therapy (141) 141
risk factors (140) 140
aggressive behavior (138) 138
high-dose chemotherapy (137) 137
neoplasm staging (137) 137
expression (135) 135
lymphoma, large b-cell, diffuse - pathology (135) 135
recurrence (132) 132
bone-marrow-transplantation (130) 130
diagnosis (123) 123
research (122) 122
positron-emission-tomography (119) 119
diffuse large b-cell lymphoma (116) 116
follow-up studies (116) 116
immunohistochemistry (115) 115
lymphoma, large b-cell, diffuse - mortality (112) 112
disease (111) 111
antineoplastic combined chemotherapy protocols - adverse effects (110) 110
3-weekly chop chemotherapy (108) 108
leukemia (107) 107
remission induction (106) 106
non-hodgkin's lymphomas (105) 105
antineoplastic agents - therapeutic use (104) 104
lymphoma, non-hodgkin - pathology (102) 102
malignant-lymphoma (102) 102
transplantation, autologous (100) 100
hemic and lymphatic diseases (99) 99
trial (99) 99
chop (98) 98
phase-ii (96) 96
etoposide - administration & dosage (95) 95
lymphoma, non-hodgkin - mortality (95) 95
surgery (95) 95
animals (93) 93
lymphoma, large b-cell, diffuse - therapy (93) 93
stem cells (93) 93
cyclophosphamide - therapeutic use (92) 92
fdg-pet (91) 91
health aspects (91) 91
hematology, oncology and palliative medicine (91) 91
radiotherapy (91) 91
classification (90) 90
lymphoma, non-hodgkin - therapy (89) 89
genetic aspects (88) 88
radiology, nuclear medicine & medical imaging (88) 88
aggressive variants (86) 86
chemotherapy plus rituximab (86) 86
antibodies, monoclonal, murine-derived (85) 85
bone-marrow transplantation (84) 84
follicular lymphoma (83) 83
immunology (82) 82
gene expression (81) 81
vincristine - therapeutic use (81) 81
cyclophosphamide (79) 79
doxorubicin - therapeutic use (78) 78
etoposide (78) 78
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1821) 1821
German (26) 26
French (24) 24
Spanish (10) 10
Japanese (7) 7
Russian (6) 6
Korean (5) 5
Italian (3) 3
Polish (3) 3
Chinese (1) 1
Dutch (1) 1
Portuguese (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


American Journal of Hematology, ISSN 0361-8609, 05/2014, Volume 89, Issue 5, pp. 536 - 541
Increasing dose intensity (DI) of chemotherapy for patients with aggressive non‐Hodgkin lymphoma (NHL) may improve outcomes at the cost of increased toxicity.... 
B-CELL LYMPHOMA | EPIRUBICIN | 3-WEEKLY CHOP CHEMOTHERAPY | AGGRESSIVE LYMPHOMAS | INTENSITY | NON-HODGKINS-LYMPHOMA | YOUNG-PATIENTS | PROGNOSTIC-SIGNIFICANCE | HEMATOLOGY | CHEMOTHERAPY PLUS RITUXIMAB | ELDERLY-PATIENTS | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Follow-Up Studies | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Epirubicin - administration & dosage | Recombinant Proteins - adverse effects | Cyclophosphamide - adverse effects | Filgrastim | Young Adult | Vincristine - administration & dosage | Adult | Female | Lymphoma, Non-Hodgkin - drug therapy | Granulocyte Colony-Stimulating Factor - adverse effects | Prednisone - administration & dosage | Prednisone - adverse effects | Recombinant Proteins - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Vincristine - adverse effects | Aged | Epirubicin - adverse effects | Granulocyte Colony-Stimulating Factor - administration & dosage | Care and treatment | Anthracyclines | Chemotherapy | Biological products | Corticosteroids | Granulocyte colony-stimulating factor | Leukemia | Lymphomas | Product development | Dosage and administration | Standards | Cancer | Index Medicus
Journal Article
Cancer, ISSN 0008-543X, 04/2015, Volume 121, Issue 7, pp. 1032 - 1039
Journal Article
Journal Article
Journal Article
Blood, ISSN 0006-4971, 11/2010, Volume 116, Issue 18, pp. 3418 - 3425
Journal Article
Journal of Clinical Investigation, ISSN 0021-9738, 10/2012, Volume 122, Issue 10, pp. 3416 - 3423
Mantle cell lymphoma is a B cell malignancy in which constitutive dysregulation of cyclin D1 and the cell cycle, disruption of DNA damage response pathways,... 
B-CELLS | MEDICINE, RESEARCH & EXPERIMENTAL | PHASE-II TRIAL | SINGLE-AGENT TEMSIROLIMUS | CYCLIN D1 | CONSTITUTIVE ACTIVATION | THERAPEUTIC TARGET | CLINICAL-TRIALS | GENE-EXPRESSION | TRANSCRIPTIONAL ROLE | AGGRESSIVE VARIANTS | Complementarity Determining Regions - genetics | Translocation, Genetic | Humans | Neoplasm Proteins - physiology | Lymphoma, Mantle-Cell - pathology | Apoptosis - genetics | DNA Repair - genetics | Molecular Targeted Therapy | Cyclin D1 - physiology | Cell Transformation, Neoplastic - genetics | Neoplastic Stem Cells - pathology | B-Lymphocytes - pathology | Neoplasm Proteins - genetics | Lymphoma, Mantle-Cell - genetics | Stem Cell Niche | Chromosomes, Human, Pair 11 - ultrastructure | Neoplasm Invasiveness | Neoplasm Proteins - biosynthesis | Genes, bcl-1 | Lymphoma, Mantle-Cell - drug therapy | Chromosomes, Human, Pair 11 - genetics | Cyclin D1 - biosynthesis | Lymphoma, Mantle-Cell - etiology | Signal Transduction - genetics | Germinal Center - pathology | Disease Progression | Genes, Immunoglobulin | Clone Cells - pathology | Gene Rearrangement, B-Lymphocyte, Heavy Chain | Signal Transduction - physiology | Chromosomes, Human, Pair 14 - ultrastructure | Chromosomes, Human, Pair 14 - genetics | Immunoglobulin Heavy Chains - genetics | DNA damage | Mantle cell lymphoma | Physiological aspects | Cyclin D proteins | Genetic aspects | Research | Risk factors | Review Series
Journal Article
Journal Article